Latest News

Focusing on cutting-edge technologies and research advancements,
sharing Aniphe BioLab’s achievements in scientific innovation, Professional insights
and practical experience in the fields of laboratory animals and preclinical research.

Publish an article

2026-10-29

Naming Genetically Engineered Mice (Part II): From Being Understandable to Being Written Correctly

2026-10-29

How should a multi-disease composite mouse model be constructed? Let’s take a look at the CKM approach.

2026-08-12

2026 CKM Guidelines Released: Chronic Diseases Enter the Era of Integrated Cardiorenal-Metabolic Management—It’s Time to Rethink Animal Models

2026-08-12

A Guide to Safe Mouse Handling | Manual on Mouse Transport Protocols and Troubleshooting

Seemingly compliant, yet a major setback! Listen as laboratory mice reveal the hidden risks of drug efficacy, and break the deadlock with end-to-end QA oversight.

I am a laboratory mouse used in in vivo pharmacological efficacy studies. Over the years, I have witnessed numerous experiments. Some projects followed rigorous procedures and maintained thorough documentation, resulting in smooth publication and robust support. IND Submission: Some projects, despite investing several months and substantial funding, were found to have unreliable data during verification.

Many people assume that the greatest risk in animal research is data fabrication; in reality, a more common issue is that researchers, while not intentionally falsifying results, fail to adhere to standardized experimental protocols, leading to a lack of traceability and reproducibility in the data. For long‑term, high‑cost models—such as humanized mice or large animals with metabolic diseases—these problems can be far more consequential than one might expect.

01 Compliance Bottlenecks in Long-Term Models: The Cumulative Effects of Operational Deviations

As a mouse who spends every day in the animal facility, I’ve noticed an interesting phenomenon: in many projects, problems ultimately arise not because someone deliberately fabricated data, but because everyone assumes that certain details are good enough to be overlooked.

In preliminary experiments with conventional mice, some procedural errors may still be tolerable; however, long‑term models such as humanized mice and large animals with metabolic disorders are quite different. A slight discrepancy in weighing, a delayed administration time, or an incomplete behavioral recording—though they may seem minor and go unnoticed at first—can, when accumulated over the entire experimental period, be just as detrimental as deliberate data fabrication.

02 Three Major Hidden Flaws Affecting the Quality of Drug Efficacy Evaluation Data

Flaw 1: Inaccurate weight measurement, leading to dosage errors right from the first step.

Body weight is a critical factor in calculating drug dosages. However, in practice, it is common to see situations where mice are weighed on an empty stomach one day and after a meal the next, with measurements taken once during the morning shift and again during the evening shift, while the data are first recorded on paper and only entered into the database several days later. The fluctuations in body weight before and after feeding can reach 10% In summary, this means that, under the same dosing regimen, the actual dose may have already been altered.

The bigger issue is that, without real-time logging and timestamps, it becomes extremely difficult to trace the root cause of any anomalous data once it’s detected.

Flaw 2: Inconsistent dosing times lead to a gradual distortion of drug efficacy assessments.

For chronic disease models, tumor models, and targeted‑drug studies, the dosing frequency and interval directly influence drug exposure levels. However, in real‑world projects, factors such as shift schedules and holidays often lead to deviations—administering a dose earlier today and later tomorrow, with different personnel following varying routines. While one or two instances may seem insignificant, over the course of an entire experimental cycle, the resulting pharmacodynamic outcomes can exhibit substantial bias.

If issues such as cross-contamination of equipment and residual drug solution coexist, it may even become impossible to determine whether abnormal data stem from the drug itself or from procedural deviations.

Vulnerability 3: Behavioral records are often retroactively completed, making them the most prone to issues during review and evaluation.

Behavioral assessment is a critical endpoint in research on neurological disorders, pain models, and metabolic diseases—but it is also the most easily overlooked step. Many laboratories still rely on simple observation. → Handwritten record → Post‑experiment data organization. As the experimental period was extended, some data had to be supplemented retrospectively based on recollection.

Under current regulatory review requirements, behavioral outcome data that lack real-time recording, original timestamp information, and the ability to demonstrate the data‑generation process are significantly compromised in terms of credibility. In many cases, the ultimate issue is not that the drug is ineffective, but rather that the data fail to substantiate its efficacy.

03 Systematic control to eliminate human error in experiments.

In long-term animal studies, procedures such as weighing, drug administration, behavioral assessments, and data recording are tightly interlinked; any deviation at a single stage can compromise the final outcomes.

Data quality depends not on any one person’s diligence, but on a well‑standardized process. When systems replace intuition and workflows supplant memory, every action is recorded and traceable, ensuring that experimental results can truly withstand peer review and validation.

04 Safeguarding Data Value: Long-Term Projects QA Control logic

In long‑term projects, the true cost is never just the expense of a single animal; it is the value of the data accumulated over the entire experimental cycle. Building a model can take months, and if data become invalid due to missing records, batch mix-ups, or procedural biases, the resulting losses often cannot be quickly offset by repeating experiments.

Therefore, during project execution, Aniphe BioLab not only focuses on the success of the model but also ensures that the entire experimental process can withstand rigorous traceability and verification. For long‑term pharmacodynamic evaluation projects, we have established a system that covers every stage of the experimental workflow. QA Management System:

Key operational nodes are recorded in real time, with timestamp information automatically retained.
Animals from different batches are individually identified and managed in designated zones.
Administration, weighing, and behavioral observations were conducted strictly in accordance with SOP Execution;
Deviation incidents are fully traceable and handled in a closed-loop manner.
QA Participate in the review and oversight of key milestones.
For pharmacological efficacy evaluation projects, the final deliverable is not merely the experimental results, but rather a complete, traceable, and verifiable data chain.